stockrow
Saturday 7 November 2026
Export NUVB’s income statement to Excel — free account
Nuvation Bio Inc.
NUVB Healthcare Biotechnology
Nuvation Bio Inc.’s revenue for fiscal 2025 (year ended December 2025) was $62.9 million, up 699.0% from fiscal 2024.
- Revenue
- +242.6%
- EPS
- +25.6%
- Free cash flow
- +34.1%
- Total debt
- +441.5%
Quarter to September 2026, against a year earlier
4.17
0.02
−0.48%
Follow NUVB
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
48.65 | 10.42 | 11.66 | 9.77 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(102.92) | 293.95 | (46.10) | (51.10) | |
P/B ratio |
10.01 | 4.66 | 7.80 | 8.64 | |
Price to Tangible BV |
10.39 | 4.83 | 8.13 | 9.47 | |
EV/Sales |
41.08 | 7.06 | 9.23 | 7.89 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(14.90) | (8.03) | (13.01) | (15.00) | |
EV/FCF |
(14.87) | (8.01) | (12.97) | (14.72) | |
Quick Ratio |
6.67 | 7.04 | 7.98 | 7.14 | |
Current Ratio |
6.95 | 7.44 | 8.37 | 7.45 | |
Net Debt/EBITDA |
14.36 | (101.44) | 8.22 | 9.20 | |
Debt/Assets |
8.90% | 8.70% | 33.38% | 36.67% | |
Debt/Equity |
0.17 | 0.17 | 0.98 | 1.25 | |
Asset Turnover |
0.11 | 0.26 | 0.24 | 0.29 | |
Operating CF/Net income |
0.81 | 0.94 | 0.68 | 0.92 | |
Capex/Depreciation |
(0.10) | (0.06) | (0.29) | (1.43) | |
Interest Coverage |
(5.10) | 0.58 | (7.55) | (6.90) | |
Research and Development Expense of Revenue |
81.92% | 42.11% | 96.76% | 72.70% | |
Selling, General and Administrative Expense of Revenue |
96.32% | 46.03% | 134.41% | 94.67% | |
Intangible Assets out of Total Assets |
0.02 | 0.02 | 0.01 | 0.03 | |
Share Based Compensation of Revenue |
19.08% | 10.85% | 33.01% | 22.40% | |
Graham Net Nets |
0.09 | 0.20 | 0.12 | 0.09 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(6.70%) | (9.90%) | (7.65%) | (7.03%) | |
Free Cash Flow Yield |
(5.68%) | (8.46%) | (6.10%) | (5.49%) | |
Revenue per Share |
0.12 | 0.24 | 0.09 | 0.13 | |
Operating CF per Share |
(0.09) | 0.01 | (0.12) | (0.11) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.09) | 0.01 | (0.12) | (0.11) | |
Cash per Share |
1.55 | 1.54 | 1.90 | 1.89 | |
Shareholders Equity per Share |
0.90 | 0.92 | 0.73 | 0.65 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.90 | 0.92 | 0.73 | 0.65 | |
Free Cash Flow |
(29.82) | 5.02 | (43.22) | (40.15) | |
Working Capital |
489.29 | 512.01 | 639.68 | 636.10 | |
Capital Expenditures |
(0.09) | (0.05) | (0.25) | (1.59) | |
Net Current Asset Value |
282.41 | 300.85 | 235.79 | 184.24 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.01 | 0.04 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
17.83 | 15.72 | 19.20 | 27.04 | |
Average Payables |
7.91 | 16.49 | 17.25 | 12.40 | |
Average Inventory |
— | 7.93 | 10.23 | 10.52 | |
Average Assets |
567.72 | 551.37 | 695.86 | 689.98 | |
Average Common Equity |
384.75 | 369.51 | 313.39 | 276.93 |
Columns are period end dates · fundamentals updated 6 Nov 2026